Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study

Published:2021-09-26 Issue:21 Volume:10 Page:7593-7600
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Liu Zhiyong¹^ORCID,Gao Songtao²,Zhu Liangyu³,Wang Jiaqiang¹,Zhang Peng¹,Li Po¹,Zhang Fan¹,Yao Weitao¹

Affiliation:

1. Department of Orthopedics The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou Henan China

2. Department of Orthopedics Henan Provincial People's Hospital and People's Hospital of Zhengzhou University Zhengzhou Henan China

3. Department of Orthopedics Zhengzhou Orthopedics Hospital Zhengzhou Henan China

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4286

Reference27 articles.

1. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study

2. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy

3. Osteosarcoma, Chondrosarcoma, and Chordoma

4. Ewing’s Sarcoma

5. Chordoma: current concepts, management, and future directions

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma;Cells;2024-06-04

2. Recurrent retroperitoneal liposarcoma with multiple surgeries: a case report;Frontiers in Oncology;2024-05-03

3. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study;Frontiers in Immunology;2024-03-22

4. The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma;Cancer Cell International;2023-12-05

5. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa;Journal of Bone Oncology;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3